Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.

Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R

The lancet. Diabetes & endocrinology9 Jun 2019Cited by 51 (Europe PMC)

PMID31189519DOI10.1016/s2213-8587(19)30184-6PepBankPUB-31189519

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In insulin-naive adults with type 2 diabetes, IDegLira (degludec plus liraglutide) gave a longer time until treatment intensification was needed than insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, the combination product IDegLira kept blood sugar controlled for longer than insulin glargine before more treatment was needed.
Peptide
Liraglutide
Outcome
IncreaseTime to treatment intensification
Study
n = 1,012
Comparator
Insulin glargine U100
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median time to intensification
> 2 years
IDegLira
Median time to intensification
≈ 1 year
IGlar U100
Source sentences
Summary
Patients in the IDegLira group had significantly longer time until intensification was needed than those in the IGlar U100 group (median >2 years vs about 1 year).
1 context sentence(design, population, supporting numbers)
Summary · context
DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3118951901
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In insulin-naive adults with type 2 diabetes, fewer patients on IDegLira (degludec plus liraglutide) needed treatment intensification over 104 weeks than on insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, fewer people on the combination product IDegLira needed extra treatment over 104 weeks than on insulin glargine.
Peptide
Liraglutide
Outcome
DecreasePatients needing treatment intensification over 104 weeks
Study
n = 1,012
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients needing intensification
37%
IDegLira
Patients needing intensification
66%
IGlar U100
Source sentences
Summary
Fewer patients in the IDegLira group needed treatment intensification over 104 weeks than those in the IGlar U100 group (189 [37%] of 506 vs 335 [66%] of 506).
1 context sentence(design, population, supporting numbers)
Summary · context
DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3118951902
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In insulin-naive adults with type 2 diabetes, preplanned sensitivity analyses agreed with the primary analysis and favoured IDegLira (degludec plus liraglutide) over insulin glargine U100.
In plain wordsIn adults with type 2 diabetes, extra checks of the main result also favoured the combination product IDegLira over insulin glargine.
Peptide
Liraglutide
Outcome
DecreaseTime to intensification, sensitivity analysis
Study
n = 1,012
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Hazard ratio
0.45
IDegLira vs IGlar U100
Source sentences
Summary
The preplanned sensitivity analyses of the primary endpoint were in agreement with the primary analysis (hazard ratio 0·45 [95% CI 0·38-0·54]) in the proportional hazards regression model and the generalised log-rank test was also in favour of IDegLira (p<0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3118951903
04HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In insulin-naive adults with type 2 diabetes, no new or unexpected safety and tolerability issues were identified with IDegLira (degludec plus liraglutide).
In plain wordsIn adults with type 2 diabetes, no new or unexpected safety problems were found with the combination product IDegLira.
Peptide
Liraglutide
Outcome
No significant changeNew or unexpected safety and tolerability issues
Study
n = 1,012
Comparator
Insulin glargine U100
Outcome group
Adverse events · Whole body
Source sentences
Summary
No new or unexpected safety and tolerability issues were identified
1 context sentence(design, population, supporting numbers)
Summary · context
DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3118951904
05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In insulin-naive adults with type 2 diabetes, there were no treatment-related deaths.
In plain wordsIn adults with type 2 diabetes, no deaths were linked to the treatment.
Peptide
Liraglutide
Outcome
No significant changeTreatment-related deaths
Study
n = 1,012
Comparator
Insulin glargine U100
Outcome group
Mortality · Whole body
Source sentences
Summary
there were no treatment-related deaths.
1 context sentence(design, population, supporting numbers)
Summary · context
DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3118951905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02501161

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 1,01231 Jan 2016 to 3 Oct 2018

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 27 Nov 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.